David Stark - Teva Pharmaceutical Executive Vice President, Chief Legal Officer
TEVA Stock | ILA 4,978 25.00 0.50% |
President
Mr. David Matthew Stark serves as Executive Vice President, Chief Legal Officer of Teva Pharmaceutical Industries Limited. Mr. Stark became Executive Vice President, Chief Legal Officer in November 2017. From November 2016 to November 2017, he served as Group Executive Vice President, Chief Legal Officer. From 2014 to 2015, Mr. Stark was Senior Vice President and General Counsel, Global Specialty Medicines. Since joining Teva in 2002, Mr. Stark served in a series of roles with increasing responsibilities in Teva North America and Teva Americas, including as Senior Director, Deputy General Counsel, and Vice President and General Counsel. Prior to joining Teva, Mr. Stark was an associate attorney in the litigation departments at Willkie Farr Gallagher LLP between 1998 and 2002, Chadbourne Parke between 1997 and 1998 and Haight, Gardner, Poor Havens between 1994 and 1997 since 2016.
Age | 54 |
Tenure | 8 years |
Phone | (972) 3 914 8213 |
Web | www.tevapharm.com |
David Stark Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Stark against Teva Pharmaceutical stock is an integral part of due diligence when investing in Teva Pharmaceutical. David Stark insider activity provides valuable insight into whether Teva Pharmaceutical is net buyers or sellers over its current business cycle. Note, Teva Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Teva Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Stark over a year ago Exercise or conversion by David Stark of 18430 shares of Teva Pharma subject to Rule 16b-3 |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 1 records | PRESIDENT Age | ||
Zurit Levine | Compugen | 55 |
Management Performance
Return On Equity | -0.24 | |||
Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Moshe Many, Independent Director | ||
Richard Daniell, Executive Vice President - European Commercial | ||
Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
Ronit SatchiFainaro, Independent Director | ||
Richard Lerner, Independent Director | ||
Galia Maor, Independent Director | ||
Janet Vergis, Independent Director | ||
Carlo Notaristefani, CEO of Global Operations and President of Global Operations | ||
JeanMichel Halfon, Statutory - independent director | ||
Eli Shani, Ex Portfolio | ||
Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations | ||
Abbas Hussain, Independent Director | ||
Yitzhak Peterburg, Director | ||
Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
Perry Nisen, Independent Director | ||
Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director | ||
David Stark, Executive Vice President, Chief Legal Officer | ||
Amir Elstein, Vice Chairman of the Board | ||
Dan Suesskind, Director | ||
Arie Belldegrun, Independent Director | ||
Richard Egosi, Chief Legal Officer and Group Executive VP | ||
Andrew Weil, Chief Accounting Officer | ||
Jean Halfon, Statutory - independent director | ||
Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio | ||
Robert Koremans, President CEO-Global Specialty Medicines | ||
Gerald Lieberman, Independent Director | ||
Roberto Mignone, Independent Director | ||
Rosemary Crane, Independent Director | ||
Nechemia Peres, Independent Director | ||
Roger Abravanel, Independent Director | ||
Eyal Desheh, CFO and Group Executive VP | ||
Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
Kare Schultz, CEO Pres | ||
Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication | ||
Amir Weiss, VP Officer | ||
Brendan OGrady, Executive Vice President - North America Commercial | ||
Michael Hayden, President - Global Research and Development, Chief Scientific Officer | ||
Gabrielle Sulzberger, Statutory Independent Director | ||
Eric Drape, Executive Vice President - Global Operations | ||
Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee | ||
Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director | ||
Kathleen Veit, Global VP | ||
Joseph Nitzani, Independent Director | ||
Deborah Griffin, Chief Accounting Officer | ||
Timothy Wright, Head - Business Development, Strategy and Innovation | ||
Sigurdur Olafsson, President and CEO - Global Generic Medicines Group | ||
Murray Goldberg, Independent Director | ||
Dan Propper, Independent Director | ||
Ory Slonim, Independent Director | ||
Michael McClellan, Chief Financial Officer, Executive Vice President | ||
Kevin Mannix, Vice President Head of Investor Relations | ||
Kaare Schultz, President, Chief Executive Officer, Director | ||
Sol Barer, Independent Chairman of the Board | ||
Eli Kalif, Chief Financial Officer, Executive Vice President, Director |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.24 | |||
Return On Asset | 0.0363 | |||
Profit Margin | (0.16) % | |||
Operating Margin | 0.18 % | |||
Current Valuation | 102.13 B | |||
Shares Outstanding | 1.11 B | |||
Shares Owned By Insiders | 0.77 % | |||
Shares Owned By Institutions | 5.30 % | |||
Price To Book | 1.18 X | |||
Price To Sales | 2.32 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Teva Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Teva Pharmaceutical's short interest history, or implied volatility extrapolated from Teva Pharmaceutical options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Teva Stock analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |